Wells Fargo Maintains Equal-Weight on Alnylam Pharmaceuticals, Lowers Price Target to $253
Wells Fargo analyst Derek Archila maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Equal-Weight and lowers the price target from $256 to $253.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga